Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 13/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | BLVRB | P30043 | 1/20 | 0.61 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379629 | 0.93 | KDM4E (0.65) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL3384040 | 0.91 | XDH (0.60) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL19523320 | 0.91 | RAB9A (0.67) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL19523322 | 0.91 | XDH (0.63) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL19523351 | 0.90 | XDH (0.65) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL1331619 | 0.90 | XDH (0.66) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL3568142 | 0.89 | XDH (0.64) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL1357282 | 0.89 | XDH (0.60) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL1357815 | 0.88 | XDH (0.68) | XDHSMN1; SMN2ABCC4ABCB11PGR | |
| SCHEMBL19523350 | 0.88 | XDH (0.65) | XDHSMN1; SMN2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | claimed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | claimed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | claimed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | claimed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | claimed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | claimed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | claimed |
| US-9802907-B2 | 2-aryl selenazole compound and pharmaceutical composition thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-8426453-B2 | Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid | ASTELLAS PHARMA INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | XDH 1/4885SMN1; SMN2 4732/4885ABCC4 598/4885 |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | XDH, NLRP3, UACA | XDH 1/4885SMN1; SMN2 3060/4885ABCC4 448/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | XDH 1/4885SMN1; SMN2 4732/4885ABCC4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.